HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takako Furukawa Selected Research

copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)

9/2015A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
9/2015Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission.
9/2014Comparison of intratumoral FDG and Cu-ATSM distributions in cancer tissue originated spheroid (CTOS) xenografts, a tumor model retaining the original tumor properties.
2/2012Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation.
5/2009Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model.
8/2008[Development of in vivo imaging system targeting a molecular marker].
8/2006Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takako Furukawa Research Topics

Disease

47Neoplasms (Cancer)
08/2021 - 10/2004
13Hypoxia (Hypoxemia)
01/2018 - 05/2002
5Pancreatic Neoplasms (Pancreatic Cancer)
11/2017 - 05/2011
5Neoplasm Metastasis (Metastasis)
04/2017 - 05/2011
5Mesothelioma
05/2011 - 09/2007
4Carcinogenesis
03/2015 - 09/2007
3Carcinoma (Carcinomatosis)
10/2017 - 02/2011
3Prostatic Neoplasms (Prostate Cancer)
01/2013 - 10/2004
2Melanoma (Melanoma, Malignant)
10/2014 - 01/2012
2Hepatocellular Carcinoma (Hepatoma)
12/2012 - 07/2012
2Alzheimer Disease (Alzheimer's Disease)
02/2012 - 02/2009
2Malignant Mesothelioma
05/2011 - 09/2007
1Autoimmune Diseases (Autoimmune Disease)
03/2022
1Proteinuria
03/2022
1Glomerulonephritis
03/2022
1Nephritis
03/2022
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
03/2022
1Colonic Neoplasms (Colon Cancer)
04/2016
1Glioblastoma (Glioblastoma Multiforme)
01/2016
1Breast Neoplasms (Breast Cancer)
10/2015
1Chromosome Aberrations (Chromosome Abnormalities)
09/2015
1Colorectal Neoplasms (Colorectal Cancer)
01/2015
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2014

Drug/Important Bio-Agent (IBA)

10IntegrinsIBA
11/2017 - 05/2011
7Proteins (Proteins, Gene)FDA Link
01/2018 - 05/2002
7Peptides (Polypeptides)IBA
04/2017 - 08/2008
7copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA
09/2015 - 08/2006
5Pharmaceutical PreparationsIBA
10/2017 - 09/2011
5CopperIBA
09/2015 - 01/2008
5Acetates (Acetic Acid Esters)FDA Link
01/2015 - 10/2004
4ManganeseIBA
05/2011 - 01/2008
4EnzymesIBA
10/2009 - 04/2003
3Therapeutic UsesIBA
11/2017 - 11/2008
3cyclic arginine-glycine-aspartic acid peptideIBA
04/2017 - 04/2014
3Radioisotopes (Radionuclides)IBA
06/2016 - 01/2016
3ThymidineIBA
04/2016 - 01/2006
3Acetyl Coenzyme A (Acetyl-CoA)IBA
01/2015 - 05/2009
3Monoclonal AntibodiesIBA
01/2015 - 07/2012
3ApoferritinsIBA
06/2013 - 09/2007
3ErbB Receptors (EGF Receptor)IBA
07/2012 - 08/2010
3Indicators and Reagents (Reagents)IBA
02/2012 - 08/2006
3Superoxide DismutaseIBA
05/2011 - 01/2008
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
05/2009 - 01/2006
2Immunoglobulin G (IgG)IBA
03/2022 - 11/2012
2Yttrium-90IBA
11/2017 - 06/2016
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2017 - 05/2011
2arginyl-glycyl-aspartic acidIBA
04/2017 - 01/2016
2Antineoplastic Agents (Antineoplastics)IBA
04/2016 - 05/2009
2Red Fluorescent ProteinIBA
04/2016 - 11/2008
2DNA (Deoxyribonucleic Acid)IBA
09/2015 - 05/2002
2Diacetyl (Biacetyl)IBA
09/2015 - 02/2012
2AntibodiesIBA
01/2015 - 08/2008
2pimonidazoleIBA
09/2014 - 05/2009
264Cu- cyclam- RAFT- cyclo(arginyl- glycyl- aspartyl- phenylalanyl- lysyl)4IBA
12/2012 - 05/2011
2Oxygen (Dioxygen)IBA
02/2012 - 10/2009
2Biological ProductsIBA
02/2012 - 08/2008
2AsbestosIBA
05/2011 - 09/2007
2Phosphotransferases (Kinase)IBA
08/2010 - 08/2008
2Acetate-CoA Ligase (Acetyl CoA Synthetase)IBA
10/2009 - 05/2009
1AutoantigensIBA
03/2022
1AutoantibodiesIBA
03/2022
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
03/2022
1cathepsin SIBA
03/2022
11,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
08/2021
1Immunoglobulin FragmentsIBA
08/2021
1Carrier Proteins (Binding Protein)IBA
11/2017
1Eukaryotic Initiation Factor-4EIBA
11/2017
1dactolisibIBA
11/2017
1Ribosomal Protein S6IBA
11/2017
1Bevacizumab (Avastin)FDA Link
10/2017
1Angiogenesis InhibitorsIBA
10/2017
1Fluorouracil (Carac)FDA LinkGeneric
04/2016
1regorafenibIBA
04/2016
1AntimetabolitesIBA
01/2016
1Nucleic AcidsIBA
01/2016
1SolutionsIBA
01/2016
1Trastuzumab (Herceptin)FDA Link
10/2015
1RadiopharmaceuticalsIBA
10/2015
1Immunoconjugates (Immunoconjugate)IBA
10/2015
1Nuclear Localization Signals (Nuclear Localization Signal)IBA
10/2015
1IsotopesIBA
09/2015
1SemicarbazonesIBA
09/2015
1NitroimidazolesIBA
09/2015
1Fatty Acids (Saturated Fatty Acids)IBA
01/2015
1Biomarkers (Surrogate Marker)IBA
01/2015
1Integrin alpha5beta1IBA
01/2015
1N-methylbenzamideIBA
10/2014
1Glutamic Acid (Glutamate)FDA Link
10/2014
1Oncogene Proteins (Oncogene Protein)IBA
10/2014
1Hematoxylin (Haematoxylon)IBA
09/2014

Therapy/Procedure

15Therapeutics
10/2017 - 01/2008
8Radiotherapy
10/2017 - 01/2005
6Precision Medicine
10/2017 - 01/2014
4Radioimmunotherapy
08/2021 - 10/2015
3Drug Therapy (Chemotherapy)
05/2013 - 01/2006
1Oral Administration
03/2022
1Brachytherapy
01/2021
1Adjuvant Chemotherapy
04/2016
1Aftercare (After-Treatment)
05/2015
1Transplantation
03/2015